Purpose To analyze the therapeutic indications for off-label use of rituximab, the available evidence for its use, the outcomes, and the cost. Methods This was a retrospective analysis of patients treated with rituximab for off-label indications from January 2007 to December 2009 in two tertiary hospitals. Information on patient characteristics, medical conditions, and therapeutic responses was collected from medical records. Available evidence for the efficacy of rituximab in each condition was reviewed, and the cost of treatment was calculated. Results A total of 101 cases of off-label rituximab use were analyzed. The median age of the patients involved was 53 [interquartile range (IQR) 37.5-68.0] years; 55.4 % were women. The indications for prescribing rituximab were primarily hematological diseases (46 %), systemic connective tissue disorders (27 %), and kidney diseases (20 %). Available evidence supporting rituximab treatment for these indications mainly came from individual cohort studies (53.5 % of cases) and case series (25.7 %). The short-term outcome (median 3 months, IQR 2-4 months) was a complete response in 38 % of cases and partial response in 32.6 %. The highest short-term responses were observed for systemic lupus erythematosus and membranous glomerulonephritis, and the lowest was for neuromyelitis optica, idiopathic thrombocytopenic purpura, and miscellaneous indications. Some response was maintained in long-term follow-up (median 23 months IQR 12-30 months) in 69.2 % of patients showing a short-term response. Median cost per patient was € 5,187.5 (IQR € 5,187.5-7,781.3). Conclusions In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among
Introduction
In Spain the legislation governing off-label drug prescribing changed in 2009. As a result, drugs can now be used for unapproved indications when prescribed by a physician and approved by the patient, who must consent to the treatment after being properly informed [1] . However, off-label use should be an exception and limited to situations in which there is a lack of approved alternatives for a particular patient and condition even though authorization from the Regulatory Agency is no longer required. One worry is that the easier procedure will facilitate the use of drugs with less conclusive evidence of efficacy and greater uncertainty regarding their toxicity, and often at a high cost. This possibility is a source of anxiety for hospital medical directors and healthcare managers due to doubts on the adequacy of financing drugs with insufficient or very limited data on their efficacy. Thus, in accordance with the Catalan Health Service procedures [2] , pharmacotherapeutics committees in public hospitals are required to assess each case in order to verify if the necessary conditions for off-label drug used are fulfilled and to advise hospital medical directors.
Rituximab, the first anti-CD20 monoclonal antibody to be marketed, is one of the most frequently requested offlabel drugs in hospitals [3] . CD20 antigen regulates the early steps of activation and differentiation of B lymphocytes [4] . Rituximab was approved by the European Medicines Agency (EMA) in 1998 for use in patients with stage III-IV follicular lymphoma who are chemoresistant or in their second or subsequent relapse after chemotherapy. Since then, EMA indications for rituximab have broadened, and this drug can be used in first line treatments and the maintenance of previously specified types of lymphoma. It has also been approved for CD20-positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide-hydroxydaunorubicin-vincristine-prednisolone) chemotherapy, rheumatoid arthritis, and chronic lymphocytic leukemia [5] .
Nevertheless, the use of rituximab in off-label hematological and non-hematological conditions, where B-cells and autoantibodies are thought to play an important role in their pathophysiology, is increasing. Although several authors have analyzed the off-label use of rituximab in patients with specific diseases, primarily systemic lupus erythematosus, lupus nephritis, and other severe refractory systemic autoimmune diseases [6] [7] [8] [9] [10] [11] [12] , data on its use in different off-label indications are scarce [13] [14] [15] . The aim of this study was to analyze the indications for off-label use of rituximab in our centers, the available evidence when it was used, the outcomes of treated patients, and the cost.
Methods
This was a retrospective longitudinal study of patients treated with rituximab for off-label indications from January 2007 to December 2009 in two tertiary hospitals in the Spanish public health system (Hospital Universitari Vall d'Hebron and Hospital Universitari de Bellvitge). Patients treated with rituximab were identified from a pharmacy register of requests for its off-label use. A retrospective review of medical records was conducted to obtain information on the patients (demographic data), their disease (indication for rituximab use, clinical, biological, and image data needed to analyze its stage), dosage and treatment regimen of rituximab, previous and concurrent treatments, and outcome of short and long-term after treatment with rituximab. Patients' information and their clinical progress before and after rituximab treatment were verified by conducting an audit of clinical records and consulting the clinicians responsible for the patient's care. Response was defined for each disease as complete (CR), partial (PR), or no response (NR) taking into account different parameters for each disease. In lupus nephritis and other glomerulonephritis, outcome measures mainly included proteinuria (CR: proteinuria ≤500 mg/24 h; PR: improvement ≥50 %). In patients with systemic lupus erythematosus, the symptoms and scores of disease activity were taken into account [CR: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) of ≤4 or clinical remission; PR: improvement of ≥50 % in SLEDAI]. In patients with non-Hodgkin lymphoma, response was assessed with hematological parameters and computerized tomography images (CR: normalization of nodes, spleen, liver, and biochemistry; PR: decrease of lymph node size by ≥50 %) [16] , and in patients with idiopathic thrombocytopenic purpura, the main outcome was the number of platelets (CR: platelet count of >150× 10 9 /L; PR: platelet count of >50×10 9 /L). A search in PubMed was performed to assess the available evidence on rituximab for each clinical indication when it was requested. Available evidence for each disease was classified according to the Oxford Center for Evidence-based Medicine criteria [17] . In addition, information on ongoing clinical trials for each indication of rituximab was obtained from the clinicaltrials.gov register [18] . The International Classification of Disease, tenth revision (ICD-10) was used to classify medical indications for rituximab use. To analyze the cost of treatment, the price of the drug marketed in Spain (Mabthera®) at the time of the study was taken into account. The total cost of treatment administered during the study period for each patient and for each indication was calculated.
The study was conducted according to international ethical recommendations. In accordance with the national directives in relation to post-authorization studies, the study was approved by the Ethics Committee of Clinical Investigation in each participating hospital.
The descriptive analysis of categorical and continuous variables was performed by means of the distribution of frequencies and proportions, median, and interquartile range (IQR). Statistical differences were assessed using the chisquare test. Significance was set at a level of 0.05 and was two-tailed. The statistical analysis was performed using the IBM SPSS Statistics ver. 19 statistical package (SPSS, Chicago, IL).
Results
In total, 101 cases of off-label use of rituximab were identified during the study period and included in the study for analysis. All patients were adults, with a median age of 53 (IQR 37.5-68.0) years, and 55.4 % were female. The main medical specialities of the prescribers were hematology (33.7 %), internal medicine (30.7 %), and nephrology (21.8 %). The requested indications for rituximab use were hematological neoplasms (33 %) and other hematological diseases (13 %), systemic connective tissue disorders, including lupus nephritis (27 %), kidney (20 %), and neurologic diseases (7 %) (see Table 1 ).
Most patients (97 %) had received other treatments before the request for rituximab off-label use. The median number of previous pharmacological treatments was 3 (IQR 2-4), and for hematological conditions treated with chemotherapy the median number of previous regimens was 2.5 (IQR 1-3).
Available evidence for rituximab use in these off-label indications was level 2b (based on individual cohort study) in 53.5 % of cases, level 4 (based on case series) in 25.7 %, level 2a (systematic review of cohort studies) in 10.9 % of cases, level 1a (systematic review of randomized controlled trials) in 8.9 %, and level 5 (based on expert opinion) in only 1 % of cases. Table 1 shows the levels of the available evidence for rituximab in the requested conditions. A level of evidence 1a or 2a was available in 42.5 % of hematological cases and in none of the other cases. In the majority of indications some clinical trials were ongoing: phase 3 trials for 69.3 % of requests and phase 2 for 15.8 % (see Table 1 ).
In seven cases rituximab was not administered despite the request. In chronic lymphocytic leukemia and in the majority of lymphoma cases, the most commonly prescribed dose was 375 mg/m 2 for six to eight cycles (median number of administered cycles 4). In the other diseases the dose was 1 g administered intravenously (IV) 2 weeks apart (37 cases) or 375 mg/m 2 weekly for 4 weeks (12 cases). The short-term outcome, after a median period of 3 (IQR 2-4) months, was available for 92 cases (2 were lost in follow-up), and the observed outcome was classified as a CR in 35 cases (38 %) and PR in 30 cases (32.6 %). Therefore, some response was observed in 65 (70.6 %) patients and no response was observed in 27 patients (29.4 %). The observed outcome, depending on the disease, is shown in Table 2 . The highest short-term responses, CR or PR, were observed in patients with systemic lupus erythematosus, follicular non-Hodgkin lymphoma, and membranous glomerulonephritis (100 % of cases), mantlecell non-Hodgkin lymphoma (83.3 %), and lupus nephritis (77.8 %). The lowest short-term response was observed for neuromyelitis optica and idiopathic thrombocytopenic purpura (50 %), large B-cell non-Hodgkin lymphoma (40 %), and all miscellaneous indications (pooled, 36 %).
The median long-term follow-up period was 23 (IQR 12-30) months. Over the long term, treatment in 45 of 65 patients with a short-term response (69.2 %; almost half of the total) maintained some effectiveness (29 patients with CR, 16 patients with PR), although 19 patients continued to receive other treatments or additional doses of rituximab. The long-term response was low in some hematological conditions, such as chronic lymphocytic leukemia (27.3 %) and mantle-cell non-Hodgkin lymphoma (0 %). In contrast, the long-term outcome of patients with membranous glomerulonephritis, follicular non-Hodgkin lymphoma, and lupus nephritis was high at 83.3, 75, and 72.2 %, respectively. A more detailed description of the demographics and clinical course of the patients with the most frequently presenting diseases is given in Table 3 . A relationship was found between the level of available evidence and the short-term outcome: some response (complete or partial) was described in 77.6 % of cases of diseases with a high level of evidence (1 or 2) and in 52 % of cases with a lower level of evidence (p=0.016).
At least one adverse reaction was described in the medical records of 27.7 % of patients. A total of 47 adverse reactions were registered. The most commonly reported were nausea, vomiting, diarrhea, pyrexia, sepsis, constipation, urinary tract infection, and neutropenia. Eleven adverse effects (23.4 %) were considered to be serious: seven infections, two cases of gastrointestinal bleeding, one case of edema, and one case of mucositis; in eight of these cases the patient was also treated with chemotherapy. In four patients treatment was discontinued due to the adverse drug reaction.
The total budget for rituximab treatment during the study period was € 677,901.18, and the median cost per patient was € 5,187.5 (IQR € 5,187.5-7,781.3). The most expensive indications were neuromyelitis optica, with a median treatment cost of € 14,151.3 (IQR € 5,332.6-31,820.1) and mantle-cell non-Hodgkin lymphoma (€ 6,948.7, IQR € 5,524.7-12,450); the cheapest were those in which the drug can be administered locally, such as conjunctival MALT lymphoma (€ 52) and marginal zone lymphoma of the skin (€ 521.70). The median cost during the study was slightly higher for patients with diseases having a low level of evidence (≤3) for off-label rituximab (€ 5,477.6, IQR € 3,912.6-7,781.3) than for those with a high level of evidence (€ 5,187.5, IQR € 5,187.5-8,083.3). The total cost for treating non-responders was € 171,245.37 (25.3 % of the total budget).
Discussion
The results of this study show that the off-label use of rituximab among our patient cohort was mainly for the treatment of hematological, kidney, and systemic connective tissue disorders. Available evidence for using rituximab to treat these diseases was low because it was mainly based on cohort studies and case series, while in most cases phase 3 or 2 clinical trials were ongoing at the time of our study. The short-term response was quite good, taking into account that patients were usually refractory to other treatments, and almost half of the patients maintained this response over the long term. Nevertheless, the response was variable according to the different indications. The off-label use of rituximab was very expensive. Although the off-label use of rituximab in different indications has also been assessed in other studies [13] [14] [15] , our study is the largest one to date in which evidence-based indications as well as patients' short-and long-term outcomes and cost have been evaluated.
Hematological diseases were also frequent off-label indications for the off-label prescribing of rituximab in other studies [14, 15] . Among our patient cohort, however, non-hematological indications, such as kidney and systemic connective tissue diseases, were also frequent. These results are in accordance with an increasing use of rituximab in other non-hematological off-label conditions where humoral immunity appears to play a role in their pathophysiology [13] . Few studies have assessed the level of evidence of off-label rituximab use. van Allen et al. [14] evaluated different criteria for stratifying evidence and reported that 47.1 % of cases in which rituximab was used off-label could be classified with an uncertain or inadequate evidence basis and 52.9 % with an adequate evidence basis. In our study, at the moment of the rituximab off-label request, the level of its published evidence was low and varied according to the disease, and for most conditions phase 3 or 2 clinical trials were ongoing. These results suggest that although some form of research is being carried out, decisions regarding the off-label use of rituximab are difficult to make based on available evidence at the moment of the off-label request.
The response rate in our study is comparable to that reported in other studies [13] that were also conducted in a tertiary hospital. It is noteworthy that in our study the overall rate of response included the off-label use of rituximab in diseases that have since received official authorization. Nevertheless, the exclusion of these indications did not modify the overall response rate (71.2 %). The results observed in our patients with follicular non-Hodgkin lymphoma are in accordance with those of clinical trials [19] , even though rituximab was administered with a non-authorized combination with bendamustine. In patients with chronic lymphocytic leukemia the response rate decreased during the long-term follow-up. In a randomized clinical trial using rituximab and chemotherapy, after a median follow-up of 2 years, a significantly improved progression-free survival and response rate was observed in patients who had been previously treated for chronic lymphocytic leukemia [20] . The difference between these findings and our results may be due to the patients' characteristics; in our study patients were older, and the majority (82 %) had previously been treated with two or more chemotherapeutic regimens. Otherwise, the outcomes of most patients with diffuse large B-cell non-Hodgkin lymphoma were disappointing. Early clinical trials have shown that the addition of rituximab to the CHOP regimen increases the CR rate and prolongs event-free and overall survival in elderly patients with this condition [21] [22] [23] . Once again, the poor results observed in our study might be explained by the fact that the One patient with lupus nephritis also had hemolytic anemia (hemoglobin 6 g/dl) that was resolved after treatment c Stage according to the modified Rai classification prognosis was worse in our patients which included individuals who had relapsed or had a refractory disease and because rituximab was given in combination with other chemotherapies (gemcitabine and oxaliplatin). Rituximab has not been approved for a number of other diseases, but some clinical trials have recently been published. In patients with mantle-cell non-Hodgkin lymphoma, the short-term PR and CR rate was high, but their long-term responses were null, as usual. This is in accordance with the published results [19] . Recently, the results of a clinical trial have shown that rituximab in combination with chemotherapy followed by maintenance therapy with rituximab may improve the overall long-term survival in older patients with mantle-cell lymphoma [24] .
Two clinical trials with rituximab in patients with lupus have not confirmed the efficacy suggested by case-series and recent cohort studies [6] [7] [8] [9] [10] [11] [12] . The criteria used to assess the efficacy in these trials differ from those used in our study. In the EXPLORER trial, which included patients with moderatelyto-severely active systemic lupus erythematosus, no differences in the proportion of patients achieving and maintaining a PR or CR were found between rituximab and placebo [25] . Refractory patients and those recently treated with cyclophosphamide or a calcineurin inhibitor were excluded in this trial. However, most of these patients were included in our study and other open-label studies and case reports [26] . The LU-NAR trial that included patients diagnosed as having lupus nephritis class III or IV did not find any differences in the overall response rate between rituximab and placebo [27] . Although in our study the patients were also diagnosed with lupus nephritis class III or IV and treated with mycophenolate mofetil and corticosteroids, they had a longer and more serious history of disease than the patients included in the LUNAR trial. Furthermore, the high response rate reported in the placebo arm may partially be explained by the fact that their patients were not as seriously ill as those in our study [28] .
One clinical trial has been published in adults with previously untreated primary immune thrombocytopenia [29] . The sustained response (i.e., platelet count ≥50×10 9 /L after a 6-month follow-up period) was significantly greater in patients treated with dexamethasone and rituximab than in those treated with dexamethasone alone. In a systematic review of observational studies, rituximab resulted in a pooled response rate of 62.5 % with a median duration of response of 10.5 months [30] . The response rate in our study was lower and decreased during the long-term follow-up, but rituximab was once again almost always used as the last pharmacological resource.
Rituximab off-label use was commonly requested in kidney diseases, such as glomerulonephritis, with membranous glomerulonephritis being the most frequent condition. We observed good short-term and long-term results for proteinuria in these patients, although some patients received additional doses of rituximab to maintain a lasting response. In a systematic review of case reports and case-series that included 85 patients diagnosed with membranous glomerulonephritis treated with rituximab, the reported complete remission and partial remission rates were 15-20 and 35-40 %, respectively [31] . At the present time, a number of clinical trials have been completed, but no results have yet been published.
Rituximab is very expensive, and the treatment of all of the patients in our study was costly, as has been reported in other studies on rituximab use [13, 14] . Cost is a well-disputed subject in the context of off-label drug use because casebased evidence is usually scarce and the cost-benefit rate is often uncertain. Consequently, the prescribing of off-label drugs can be controversial. Healthcare managers, doctors, the pharmaceutical industry, and patients can have different expectations, and there is a need for reliable decision-making. Physicians believe that their use may be justified based on the poor prognosis of patients and the inability of alternative treatments to achieve good results, and patients want to be cured. The pharmaceutical industry is interested in promoting the use of their drugs as much as possible, even in off-label indications [32] . Healthcare managers are reluctant to reimburse the cost of those treatments with such little scientific evidence supporting their use [33] . The off-label use of expensive drugs requires a careful evaluation of cases and reasonable expectations regarding clinical outcome. Clinical trials should be done to assess the efficacy of rituximab in off-label indications, but funding trials in rare diseases can be difficult to conduct. Meanwhile, it would seem reasonable to treat particularly severe conditions unresponsive to other therapy with a possibly effective drug albeit incomplete evidence on its efficacy. In the absence of randomized clinical trials, the results of prospective registries of patients treated in these conditions or observational studies similar to this present study may be useful.
This study has a number of limitations. Firstly, it is an observational study with a retrospective design and without a control group. Therefore the results might be biased. Secondly, we included a heterogeneous group of diseases with few cases in each group and, consequently, we have limited information. Finally, only two centers were included in our study. As a result, our findings can not be extrapolated to other hospitals in other geographical areas. However, the main strength of our study is its large size in which evidencebased indications, patients' outcomes, and cost of different off-label use of rituximab have been assessed. Moreover, the outcome survey in our study is longer than has been reported in other studies, and the participating centers are two large tertiary teaching hospitals, with all medical and surgical specialities and a high level of complexity.
In conclusion, among our patient cohort the indications for the off-label use of rituximab were variable, although hematological, kidney, and systemic connective tissue diseases were the main indications. Available evidence for rituximab in most of these settings was low, but there were ongoing clinical trials assessing its efficacy at the time. In general, short-term response was quite good, bearing in mind that patients were usually refractory to other treatments, and almost half of them maintained long-term response. In the absence of strong evidence and taking into account that clinical trials can be difficult to conduct in some rare diseases, data from prospective registers and observational studies of patients treated with off-label use of rituximab may provide useful information to improve prescribing decisions in clinical practice.
